Drugs / (Z)-n-butylidenephthalide
(Z)-n-butylidenephthalide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03234595 | Nov 2017 → Apr 2023 | glioblastoma | Everfront Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07349693 | Nov 2026 → Dec 2028 expected | IDH-wildtype glioblastoma | Everfront Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (Z)-n-butylidenephthalide | “Cerebraca Wafer (75 mg \[(Z)-n-butylidenephthalide\]) is designed for surgical combination to treat glioblastoma (GBM) diseases.” NCT03234595 ↗1“Cerebraca Wafer, (75 mg (Z)-n-butylidenephthalide, (Z)-BP, Implant)” NCT07349693 ↗ |
| Known as | (Z)-BP | “Cerebraca Wafer, (75 mg (Z)-n-butylidenephthalide, (Z)-BP, Implant)” NCT07349693 ↗ |
| Known as | Cerebraca wafer | “Cerebraca Wafer (75 mg \[(Z)-n-butylidenephthalide\]) is designed for surgical combination to treat glioblastoma (GBM) diseases.” NCT03234595 ↗ |
| Route | Other | “Cerebraca Wafer implantation” NCT03234595 ↗ |